Comparison of HIV Type 1 Protease Inhibitor Susceptibility Results in Viral Samples Analyzed by Phenotypic Drug Resistance Assays and by Six Resistance Algorithms: An Analysis of a Subpopulation of the CHORUS Cohort
- 1 August 2005
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 21 (8) , 696-701
- https://doi.org/10.1089/aid.2005.21.696
Abstract
Drug resistance testing is increasingly used to guide treatment decisions in patients infected with HIV-1. A number of rules-based algorithms have been designed to predict drug resistance profiles based on the HIV-1 genotypic data. Drug-resistance mutations in 206 viral samples from protease inhibitor (PI)-experienced subjects with HIV-1 infection were assessed, and the level of susceptibility of the samples predicted using seven unique algorithms. κ scores were used to compare agreement of results obtained using each of the predictive algorithms with the phenotypic assay results. Good overall agreement between the different algorithms and the phenotypic results was observed. Good or excellent agreement was observed between the results obtained by the predictive algorithms and the phenotypic assay results for ritonavir, indinavir, saquinavir, and nelfinavir. For amprenavir and lopinavir, there were marked differences between the different algorithms, with poor agreement (κ < 0.40) obtained with four of the seven algorithms for amprenavir. For lopinavir, poor agreement was obtained with three of seven algorithms using the 2.5-fold biological cut-off and four of seven with the clinical cut-off of 10. Atazanavir susceptibility was evaluated for concordance among six algorithms, with a range of 23–50% of the samples maintaining susceptibility. Although this cohort of patients included many who were highly antiretroviral experienced, predictive algorithms demonstrated good agreement with phenotype for several Pls. For those where discordance among algorithms existed, further improvement will likely occur as drug resistance pathways for the more recently approved PIs are elucidated.Keywords
This publication has 15 references indexed in Scilit:
- Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society–USA PanelClinical Infectious Diseases, 2003
- Improving lopinavir genotype algorithm through phenotype correlationsAIDS, 2003
- Knowledge of Genotypic Resistance Mutations Among Providers of Care to Patients with Human Immunodeficiency VirusClinical Infectious Diseases, 2003
- Antiretroviral Treatment for Adult HIV Infection in 2002JAMA, 2002
- Identification of Genotypic Changes in Human Immunodeficiency Virus Protease That Correlate with Reduced Susceptibility to the Protease Inhibitor Lopinavir among Viral Isolates from Protease Inhibitor-Experienced PatientsJournal of Virology, 2001
- Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European settingAIDS, 2001
- Patterns of Resistance Mutations to Antiretroviral Drugs in Extensively Treated HIV-1–Infected Patients With Failure of Highly Active Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Clinical Utility of Testing Human Immunodeficiency Virus for Drug ResistanceClinical Infectious Diseases, 2000
- Managing Resistance to Anti-HIV DrugsDrugs, 1999
- Activities of cefepime and five other antibiotics against nosocomial PER-1-type and/or OXA-10-type beta-lactamase-producing Pseudomonas aeruginosa and Acinetobacter spp.Journal of Antimicrobial Chemotherapy, 1998